OLFM4

Elevated expression during the early S phase of the cell cycle, followed by a gradual decrease during late S phase.

The olfactomedin-like domain is involved in the interaction with cadherin.

May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin.

N-glycosylated.

Expressed during myeloid lineage development. Much higher expression in bone marrow neutrophils than in peripheral blood neutrophils (at protein level). Strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. Overexpressed in some pancreatic cancer tissues.

• Secreted
• Extracellular space
• Mitochondrion
• Subcellular location is not clearly defined: has been shown to be secreted (PubMed:16566923), but also in the mitochondrion (PubMed:15059901, PubMed:20724538), cytoplasm and plasma membrane (PubMed:20724538) and in the nucleus (PubMed:15059901).

GW112, UNQ362/PRO698, OLFM4, Olfactomedin-4, OLM4, Antiapoptotic protein GW112, G-CSF-stimulated clone 1 protein, hOLfD, hGC-1

• entrezGene:10562
• omim:614061
• swissprot:Q6UX06

Proteins

Oncology

57280Da